ArticleJournal of Cancer2026
Subtype-Dependent Transcriptional Coupling Between DNMT1 and E2F-Linked Proliferative Programs in Breast Cancer: A Dual-Cohort Transcriptomic Analysis.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: DNMT1 is a maintenance DNA methyltransferase involved in replication-coupled epigenetic regulation and is frequently expressed in highly proliferative tumors. Although DNMT1 has been linked to RB-E2F-related transcriptional programs, the reproducibility and subtype dependence of this association in breast cancer remain incompletely defined. Methods: We performed a dual-cohort integrative transcriptomic analysis using TCGA-BRCA as the discovery cohort and METABRIC as the external validation cohort. DNMT1 expression was evaluated across tumor status and subtype annotations, with PAM50 used for all core multivariable and interaction analyses and METABRIC CLAUDIN_SUBTYPE used only for descriptive stratification. DNMT1-associated transcriptional programs were characterized in TCGA-BRCA using differential expression analysis and pathway enrichment. E2F-related transcriptional activity was summarized using an E2F metagene score derived from 122 available genes in the MSigDB Hallmark E2F Targets gene set. Cross-cohort Spearman correlation analyses, multivariable linear models, MKI67-adjusted sensitivity analyses, and likelihood-ratio tests for E2F2 × PAM50 interaction were performed. Results: DNMT1 expression was elevated in breast tumors and was highest in basal-like tumors. In TCGA-BRCA, high DNMT1 expression was associated with proliferation- and replication-related transcriptional programs, including cell-cycle progression, DNA replication, homologous recombination, and replication stress-related pathways. Across TCGA-BRCA and METABRIC, DNMT1 expression was positively associated with the E2F metagene score, E2F2, E2F3, and MKI67. In multivariable models adjusted for PAM50 subtype and age, the E2F metagene score remained associated with DNMT1 expression in both TCGA-BRCA (standardized β = 0.889, 95% CI 0.837-0.941) and METABRIC (β = 0.578, 95% CI 0.517-0.638). In joint E2F2/E2F3 models, cross-cohort evidence was strongest for E2F2, whereas the E2F3 association was more cohort-dependent and was attenuated in METABRIC. MKI67 adjustment attenuated but did not abolish the E2F2 association in both cohorts. Formal interaction testing supported subtype-dependent heterogeneity in the E2F2-DNMT1 association in both TCGA-BRCA and METABRIC. Conclusions: DNMT1 shows reproducible, subtype-dependent transcriptional coupling with E2F-linked proliferative programs in breast cancer, with the most consistent cross-cohort evidence observed for the E2F metagene score and E2F2. These findings should be interpreted as hypothesis-generating transcriptomic associations rather than evidence of direct mechanistic causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.